3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.
Neuroblastoma
BIOLOGICAL: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival, in patients in second or greater complete or very good partial remission, but at high risk of additional relapse., 2 years
Apply Real-time Quantitative RT-PCR to Test the Hypothesis That the Minimal Residual Disease Content of Bone Marrow, after the first treatments with 3F8/GMCSF has significant prognostic impact on relapse-free survival., 2 years|Monitor Safety of the High-dose Antibody Treatment, to assure no side-effects or noxious sequelae develop or emerge that were not seen in the prior phase I study., 2 years
The purpose of this study is to find out what effects, good and/or bad, the combination of 3F8 and GM-CSF has on the patient and the cancer.